Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04506463 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 397
- Enrollment target
NCT04506463: Completed Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
NCT04506463 is a Phase 2 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 397 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (198% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04506463, a Phase 2 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 397 participants
- Enrollment target
Study Summary
This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.
Primary Outcome
The pain score is based on a score of 0 to 4; the higher the score, the higher the amount of pain.
Interventions
- DRUG Placebo
- DRUG MM-II dose I
- DRUG MM-II dose II
- DRUG MM-II dose III
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2022-08-10 |
| Phase | Phase 2 |
What the finished NCT04506463 record still lists
NCT04506463 is an interventional study that assigns participants to a tested intervention. The registered 397 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (198% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04506463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04506463 about?
NCT04506463 is a clinical study titled "Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis". This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.
What is the current status of trial NCT04506463?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 397 participants. The study started on 2020-12-22. Estimated completion is 2022-08-10.
What interventions are being tested in trial NCT04506463?
The interventions under investigation include: Placebo (DRUG), MM-II dose I (DRUG), MM-II dose II (DRUG), MM-II dose III (DRUG).
Who is sponsoring clinical trial NCT04506463?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04506463's enrollment target sits among peer trials
397 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00601939 · 397 participants · NA
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
- NCT04115254 · 397 participants · NA
Stereotactic Magnetic Resonance Guided Radiation Therapy
- NCT05365581 · 398 participants · Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI